Progression-free survival was defined as the time from the start of chemotherapy to the first occurrence of disease progression or death.
Duration of EFS was computed from the date of diagnosis of ET to the first occurrence of disease, defined as local or systemic relapse or death.
Among patients who received subsequent therapy, OS was defined as the time between initiation of treatment after bevacizumab study discontinuation and death or last follow-up for surviving patients, and PFS was defined as the time between initiation of treatment after bevacizumab study discontinuation and first occurrence of disease progression or death.
In case of first occurrence of progressive disease (PFS-1) in the Cape-Bev-arm, treatment is escalated by adding irinotecan (CAPIRI-Bev).
This was necessary because of the high prevalence of PRRSV in the population and the difficultly in showing that a reported incident case truly was the first occurrence of the disease in a herd.
However, the purpose of this step was to eventually have only one, the most relevant, data point per premises - representing the first occurrence of a disease at that site.
Fourth, defining incidence by "the first occurrence of the disease in the registry" leads to overestimation of incidence in the period immediately following the initiation of the DNPR, after initiation of a screening program, or after introduction of new registry codes, due to misclassification of "backlogged" prevalent cases as incident cases.
The significant reduction in hospitalizations for cardiovascular disease differs from the nonsignificant finding for the primary end point of Look AHEAD: a composite of the first occurrence of cardiovascular disease death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for angina (16).
Inclusion criteria were an age of 18 years of older, histologically confirmed colorectal carcinoma, wild-type KRAS tumours, first occurrence of metastatic disease, at least one radiologically measurable lesion, a life expectancy of ≥12 weeks, an Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1, and adequate hematologic, hepatic and renal function.
Survival analysis was conducted considering the time from the start of the disease registration period at the experimental unit to the first occurrence of the respective disease (diarrhoea and respiratory disease).
The study endpoints were the first occurrence of coronary heart disease (CHD), stroke, heart failure (HF), total cardiovascular disease (CVD) and all-cause mortality.
